NCT05510037已完成不适用
Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 1,299
- 试验地点
- 1
- 主要终点
- overall survival
研究概览
简要总结
About a half of HER2-negative breast cancer show HER2-low expression that can be targeted by new antibody-drug conjugates. The main aim of this study is to describe the evolution of HER2 expression from primary BC to relapse by including HER2-low category in both primary and recurrent BC samples. Patients with matched primary and relapse BC samples were included. 1299 patients were included.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with available HER2 status of primary breast cancer and relapse/metastases
排除标准
- •Patients with other malignancy
结局指标
主要结局
overall survival
时间窗: up to 200 months
The overall survival (OS) was defined as time from the date of initial diagnosis of recurrent/metastatic disease to the date of death from any cause
次要结局
未报告次要终点
研究者
Jian Zhang,MD
Director of the phase I clinical trial department
Fudan University
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901HER2+ CancerNCT01526473H. Kim Lyerly22
Unknown
不适用
Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin TherapyBreast CancerNCT00530569Alberta Health services60
Unknown
不适用
Cardiotoxicity in Metastatic Her 2 Positive Patients Treated With Trastuzumab ,Pertuzumab and TaxanesCardiotoxicity.Anti Her2 Therapy.Metastatic Breast CancerNCT02101879Rambam Health Care Campus20
尚未招募
不适用
Correlation Study of Serum HER 2 Against HER 2-ADC Drug Efficacy in HER 2 Low-expressing Breast CancerHER 2 Low-expressing Breast CancerNCT06492447Tianjin Medical University Cancer Institute and Hospital50
招募中
1 期
Study of Biological Effect in Tumor Samples from Clinical Trial Patients Treated with Ds8201Patients diagnosed with advanced or metastatic cancer treated with Trastuzumab Deruxtecan in the context of a clinical trial/expanded access/ compassionate use or standard treatment, irrespective of histologic type.CTIS2023-508830-33-00Solti Group180